Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart Failure (AI-PRESENCE HF)

9 novembre 2026 aggiornato da: In-Cheol Kim, Keimyung University Dongsan Medical Center

Effects of Primary Physician Presence in SGLT2 Inhibitor-Focused Heart Failure Educational Videos During Outpatient Waiting Time on Patient Satisfaction and Educational Effectiveness : A Randomized 2x2 Factorial Study

The purpose of this study is to evaluate the effect of the primary attending physician's presence in educational videos on patient satisfaction and educational effectiveness.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The videos, generated using AI technology, focus on SGLT2 inhibitors and are provided to heart failure patients during their outpatient clinic waiting time.

In this single-center, randomized, 2x2 factorial study, participants will be assigned to one of four groups based on two factors: the specific doctor featured in the video (Doctor A vs. Doctor B) and the physician's role presentation (presented as the patient's actual attending physician vs. a non-attending general cardiologist).

All participants will watch the assigned educational video during their waiting time and then proceed with their scheduled outpatient consultation. After the consultation, participants will complete a single survey. The survey will assess overall patient satisfaction, the perceived usefulness of the education, and the objective understanding of the video's key messages regarding heart failure management and SGLT2 inhibitors.

Tipo di studio

Interventistico

Iscrizione (Stimato)

150

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Incheol Kim, MD
  • Numero di telefono: +82-53-258-4625
  • Email: kimic@dsmc.or.kr

Luoghi di studio

      • Daegu, Corea del Sud, 42601
        • Reclutamento
        • Keimyung University Dongsan Medical Center
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

19 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adults aged 19 years or older.
  • Patients diagnosed with heart failure or those visiting the cardiology outpatient clinic with suspected heart failure symptoms (e.g., dyspnea, edema).
  • Patients currently taking or scheduled to be prescribed SGLT2 inhibitors for the treatment of heart failure.
  • Patients who are able to watch the educational video during the outpatient waiting time and complete the survey after the consultation.
  • Patients who fully understand the purpose and procedures of this study and voluntarily provide written informed consent.

Exclusion Criteria:

  • Patients who do not understand the contents of this study or do not consent to the study due to cognitive decline, etc.
  • Patients with expected acute exacerbation of heart failure or a life expectancy of 1 year or less.
  • Patients who have difficulty watching the video due to visual or hearing impairments.
  • Patients scheduled for heart failure-related surgery or procedures.
  • Patients who are currently participating in, or have participated in within the past 6 months, another intervention study related to heart failure education.
  • Other patients deemed inappropriate for study participation by the investigator.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione fattoriale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Doctor A - Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as their primary physician.

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Altri nomi:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Comparatore attivo: Doctor A - Non-Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as a general cardiologist (non-attending).

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Altri nomi:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Sperimentale: Doctor B - Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as their primary physician.

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Altri nomi:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Comparatore attivo: Doctor B - Non-Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as a general cardiologist (non-attending).

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Altri nomi:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Patient Satisfaction Score
Lasso di tempo: Immediately after the outpatient clinic visit (Day 0)

Patient satisfaction regarding the positive impact and helpfulness of the educational video on the subsequent outpatient consultation process. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates a higher level of patient satisfaction.

Immediately after the outpatient clinic visit (Day 0)
Educational Usefulness Score
Lasso di tempo: Immediately after the outpatient clinic visit (Day 0)

The perceived usefulness of the educational video in understanding heart failure treatment methods, specifically the role, effects, and precautions of SGLT2 inhibitors. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates greater perceived educational usefulness and understanding.

Immediately after the outpatient clinic visit (Day 0)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Educational Content Delivery Effectiveness Score
Lasso di tempo: Immediately after the outpatient clinic visit (Day 0)

An objective assessment of the patient's understanding of the video's key messages, such as heart failure management and SGLT2 inhibitor information. It is evaluated based on the number of correct answers to 4 multiple-choice questions derived directly from the video's core content. The total score ranges from 0 to 4, where 1 point is awarded for each correct answer. A higher score indicates a better understanding and a higher level of correct knowledge acquisition.

Immediately after the outpatient clinic visit (Day 0)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

21 agosto 2026

Completamento primario (Stimato)

31 luglio 2027

Completamento dello studio (Stimato)

31 luglio 2027

Date di iscrizione allo studio

Primo inviato

9 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 2026-06-008

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .